SPRY - ARS Pharmaceuticals, Inc

Hold Momentum: Bearish

Recent News

ARS Pharmaceuticals ( NASDAQ:SPRY ) , the biopharma company developing needle-free allergy treatments, released its second-quarter 2025 results on August 13, 2025. The most significant takeaway from the release was a major GAAP revenue beat, as total GAAP revenue climbed to $15.7 million versus ...

Bullish

ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.21

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Here's What Could Help ARS Pharmaceuticals, Inc. ( SPRY ) Maintain Its Recent Price Strength

Zacks Commentary • 1 month, 2 weeks ago • score: 0.39

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.

52W High

$18.90

52W Low

$9.97

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.92

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-9.88

EV/Revenue (<3 favorable)

6.74

P/S (TTM) (<3 favorable)

8.86

P/B (<3 favorable)

5.17

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

16.83%

Institutions (25–75% balanced)

86.21%

Shares Outstanding

98,826,000

Float

52,091,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

112,339,000

Gross Profit (TTM)

90,847,000

EPS (TTM)

-0.48

Profit Margin (>10% good)

-0.43%

Operating Margin (TTM) (higher better)

-3.03%

ROE (TTM) (>15% strong)

-0.24%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

30.43

Momentum

Bearish momentum

Value

-1.8379

-1.8623

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025